Company MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

Real-time Estimate Tradegate 07:32:52 2024-05-28 EDT 5-day change 1st Jan Change
67.92 EUR -0.26% Intraday chart for MorphoSys AG -0.80% +99.71%

Business Summary

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Number of employees: 464

Sales per Business

EUR in Million2022Weight2023Weight Delta
Innovative Cancer Medicines
100.0 %
278 100.0 % 238 100.0 % -14.37%

Sales per region

EUR in Million2022Weight2023Weight Delta
United States
88.8 %
0 0.0 % 211 88.8 % -
Europe (excluding Germany)
11.2 %
-- 27 11.2 % -
Asia
0.0 %
-- 0 0.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 59 19-08-31
Director of Finance/CFO 45 23-08-06
Chief Tech/Sci/R&D Officer - 21-07-31
Chief Tech/Sci/R&D Officer 50 22-09-30
Investor Relations Contact - 06-08-31
Corporate Officer/Principal - 20-06-30
Corporate Officer/Principal 59 17-12-31
Corporate Officer/Principal - 98-12-31
Corporate Officer/Principal - 94-04-30
Comptroller/Controller/Auditor - 05-05-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 69 18-05-16
Director/Board Member 67 18-05-16
Chairman 69 12-05-30
Director/Board Member 57 22-05-17
Director/Board Member 62 16-12-31
Director/Board Member 56 19-05-21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,716,423 32,108,529 ( 85.13 %) 53,685 ( 0.1423 %) 85.13 %

Shareholders

NameEquities%Valuation
4,360,100 11.56 % 309 M €
Goldman Sachs & Co. LLC (Private Banking)
10.98 %
4,141,089 10.98 % 293 M €
Kynam Capital Management LP
10.61 %
4,000,000 10.61 % 283 M €
Adage Capital Management LP
5.011 %
1,890,000 5.011 % 134 M €
Norges Bank Investment Management
4.481 %
1,690,137 4.481 % 120 M €
RP Management LLC (Investment Management)
3.546 %
1,337,552 3.546 % 95 M €
Caligan Partners LP
2.805 %
1,057,962 2.805 % 75 M €
DWS Investment GmbH
2.301 %
868,004 2.301 % 61 M €
Baillie Gifford & Co.
2.215 %
835,292 2.215 % 59 M €
Union Investment Privatfonds GmbH
0.6550 %
247,044 0.6550 % 17 M €
NameEquities%Valuation
Glazer Capital LLC
0.9610 %
1,449,853 0.9610 % 26 M €
Balyasny Asset Management LP
0.8643 %
1,303,945 0.8643 % 24 M €
UBS Financial Services, Inc.
0.7738 %
1,167,338 0.7738 % 21 M €
Aperio Group LLC
0.6747 %
1,017,852 0.6747 % 18 M €
Carlson Capital LP
0.6300 %
950,461 0.6300 % 17 M €
Tang Capital Management LLC
0.5307 %
800,705 0.5307 % 15 M €
Slotnik Capital LLC
0.4345 %
655,519 0.4345 % 12 M €
Goldman Sachs & Co. LLC
0.4216 %
636,016 0.4216 % 12 M €
Segantii Capital Management Ltd.
0.3072 %
463,466 0.3072 % 8 M €
Tudor Investment Corp.
0.2276 %
343,310 0.2276 % 6 M €

Company contact information

MorphoSys AG

Semmelweisstrasse 7

82152, Planegg

+49 89 899 27-0

http://www.morphosys.de
address MorphoSys AG(MOR)